Abstract
Increasing evidence suggests that growth of the prostatic tissue is regulated by a network of hormones and growth factors, in which androgens play the prominent role. Hormonal manipulation remains the core of treatment for locally advanced and metastatic prostate cancer. Achievement of a complete androgen blockade, by surgical or medical means or a combination of both, offers superior results in palliative management of advanced disease. Management of hormonal refractory cancer, however, remains a challenge to clinicians.
MeSH terms
-
Adrenalectomy
-
Androgen Antagonists / therapeutic use
-
Androgens / physiology
-
Combined Modality Therapy
-
Estrogens / physiology
-
Gonadotropin-Releasing Hormone / physiology
-
Growth Hormone / physiology
-
Growth Substances / physiology
-
Humans
-
Hypophysectomy
-
Male
-
Neoplasm Staging
-
Orchiectomy
-
Progestins / physiology
-
Prolactin / physiology
-
Prostate / growth & development
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / therapy*
Substances
-
Androgen Antagonists
-
Androgens
-
Estrogens
-
Growth Substances
-
Progestins
-
Gonadotropin-Releasing Hormone
-
Prolactin
-
Growth Hormone